SULF-15 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sulf-15, and when can generic versions of Sulf-15 launch?
Sulf-15 is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in SULF-15 is sulfacetamide sodium. There are three drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the sulfacetamide sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sulf-15
A generic version of SULF-15 was approved as sulfacetamide sodium by SANDOZ on October 18th, 1988.
Summary for SULF-15
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 117 |
Patent Applications: | 819 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SULF-15 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for SULF-15
US Patents and Regulatory Information for SULF-15
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | SULF-15 | sulfacetamide sodium | SOLUTION/DROPS;OPHTHALMIC | 089047-001 | Oct 31, 1995 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |